AstraZeneca plc (LON:AZN) has been given a GBX 3,900 ($50.74) target price by investment analysts at Goldman Sachs Group Inc in a report issued on Friday. The brokerage presently has a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc’s target price would indicate a potential downside of 25.39% from the company’s previous close.

Several other equities analysts have also issued reports on AZN. JPMorgan Chase & Co. restated a “neutral” rating on shares of AstraZeneca plc in a research report on Thursday, January 26th. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research report on Friday, January 27th. Jefferies Group LLC cut their price objective on AstraZeneca plc from GBX 5,400 ($70.25) to GBX 4,800 ($62.44) and set a “buy” rating on the stock in a research report on Monday, January 30th. Liberum Capital restated a “buy” rating and issued a GBX 5,200 ($67.65) target price on shares of AstraZeneca plc in a research note on Tuesday, January 31st. Finally, Credit Suisse Group AG restated an “underperform” rating and issued a GBX 4,000 ($52.04) target price on shares of AstraZeneca plc in a research note on Friday, February 3rd. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of “Hold” and a consensus price target of GBX 5,041.80 ($65.59).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) traded up 0.35% on Friday, reaching GBX 5227.00. The company’s stock had a trading volume of 1,566,267 shares. The stock’s 50 day moving average price is GBX 4,839.40 and its 200 day moving average price is GBX 4,584.95. The firm’s market cap is GBX 66.17 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/05/26/astrazeneca-plc-azn-given-a-gbx-3900-price-target-by-goldman-sachs-group-inc-analysts-3.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

12 Month Chart for LON:AZN

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.